Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMOZ91H)

Drug Name
1H-Indole-2,3-dione Drug Info
Synonyms
Isatin; 91-56-5; Indoline-2,3-dione; 2,3-Indolinedione; INDOLE-2,3-DIONE; 2,3-Dioxoindoline; Isatine; Pseudoisatin; Isatic acid lactam; Tribulin; Isotin; 2,3-Diketoindoline; Isatinic acid anhydride; 2,3-Ketoindoline; o-Aminobenzoylformic anhydride; 2,3-Dioxo-2,3-dihydroindole; 2,3-dihydro-1H-indole-2,3-dione; NSC 9262; UNII-82X95S7M06; EINECS 202-077-8; BRN 0383659; AI3-03111; CHEMBL326294; 2,3-dihydroindole-2,3-dione; CHEBI:27539; JXDYKVIHCLTXOP-UHFFFAOYSA-N; MFCD00005718; 82X95S7M06; 84788-92-1; Isatin, 98%
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
7054
ChEBI ID
CHEBI:27539
CAS Number
CAS 91-56-5
TTD Drug ID
DMOZ91H
INTEDE Drug ID
DR1972

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DME
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Monoamine oxidase type B (MAO-B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Selegiline Hydrochloride DM3VR1L Parkinson disease 8A00.0 Approved [7]
Phenelzine DMHIDUE Depression 6A70-6A7Z Approved [8]
Tranylcypromine DMGB5RE Major depressive disorder 6A70.3 Approved [9]
Selegiline DM6034S Major depressive disorder 6A70.3 Approved [10]
Safinamide mesylate DM0J2ZT Parkinson disease 8A00.0 Approved [11]
Rasagiline DM3WKQ4 Parkinson disease 8A00.0 Approved [12]
Sulphadoxine DMZI2UF Malaria 1F40-1F45 Approved [13]
Pargyline DMM0HR1 Hypertension BA00-BA04 Approved [14]
Indeloxazine DMWO3N6 Dementia 6D80-6D86 Approved [15]
Budipine DMODHQI Migraine 8A80 Approved [16]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By NADPH-dependent carbonyl reductase 3 (CBR3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Menadione DMSJDTY Vitamin K deficiency 5B59 Approved [17]
Daunorubicin DMQUSBT Acute monocytic leukemia Approved [18]
Trastuzumab emtansine DMU1LXS HER2-positive breast cancer 2C60-2C65 Phase 2 [19]
Phenanthrene-9,10-dione DMG8KS9 Discovery agent N.A. Investigative [20]
Nitrobenzaldehyde DM4UHB5 N. A. N. A. Investigative [17]
ACMC-209cv7 DMQCSFB N. A. N. A. Investigative [17]
⏷ Show the Full List of 6 Drug(s)
Drug(s) Affected By Cytochrome P450 2E1 (CYP2E1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fomepizole DM6VOWQ Athylene glycol or methanol poisoning NE61 Approved [21]
Ademetionine DMYQDBO Hepatic fibrosis DB93.0 Approved [22]
Theophylline DMRJFN9 Bronchitis CA20 Approved [23]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [24]
Ethanol DMDRQZU Chronic pain MG30 Approved [25]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [26]
Phenobarbital DMXZOCG Cluster headache 8A81.0 Approved [27]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [28]
Didanosine DMI2QPE Human immunodeficiency virus infection 1C62 Approved [23]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [29]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 2D6 (CYP2D6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [30]
Paliperidone DM7NPJS Psychotic disorder 6A20-6A25 Approved [31]
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [32]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [33]
Oxatomide DM1F42Z Hay fever CA08.00 Approved [34]
Cinacalcet DMCX0K3 Hyperparathyroidism 5A51 Approved [35]
Capsaicin DMGMF6V Back pain ME84.Z Approved [36]
Pentamidine DMHZJCG African trypanosomiasis 1F51 Approved [37]
Quinidine DMLPICK N. A. N. A. Approved [38]
Buprenorphine DMPRI8G Opioid dependence 6C43.2Z Approved [39]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 2A6 (CYP2A6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tegafur DM31ZQM Solid tumour/cancer 2A00-2F9Z Approved [40]
Methoxsalen DME8FZ9 Cutaneous T-cell lymphoma 2B01 Approved [41]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [42]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [43]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [26]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [44]
Ifosfamide DMCT3I8 Adult central nervous system germ cell tumor Approved [45]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [46]
Letrozole DMH07Y3 Estrogen-receptor positive breast cancer Approved [47]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [48]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Aflatoxin B1 aldehyde reductase member 2 (AKR7A2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [49]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [50]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [51]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [52]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [53]
Piroxicam DMTK234 Osteoarthritis FA00-FA05 Approved [54]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [55]
Phenobarbital DMXZOCG Cluster headache 8A81.0 Approved [56]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [57]
Menadione DMSJDTY Vitamin K deficiency 5B59 Approved [58]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Aldo-keto reductase family 1 member B1 (AKR1B1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Quercetin DM3NC4M Obesity 5B81 Approved [59]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [60]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [61]
Glutathione DMAHMT9 Human immunodeficiency virus infection 1C62 Approved [62]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [63]
Disulfiram DMCL2OK Alcohol dependence 6C40.2 Approved [64]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [28]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [51]
Zoledronate DMIXC7G Adenocarcinoma 2D40 Approved [65]
Benzoic Acid DMKB9FI Alopecia areata ED70.2 Approved [64]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Dehydrogenase/reductase SDR family member 11 (DHRS11)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [5]
Quercetin DM3NC4M Obesity 5B81 Approved [5]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [60]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [66]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [50]
Flufenamic Acid DMC8VNH Dysmenorrhea GA34.3 Approved [5]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [28]
Demecolcine DMCZQGK Solid tumour/cancer 2A00-2F9Z Approved [67]
Zoledronate DMIXC7G Adenocarcinoma 2D40 Approved [65]
Temozolomide DMKECZD Adenocarcinoma 2D40 Approved [68]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Dehydrogenase/reductase SDR family member 7 (DHRS7)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Quercetin DM3NC4M Obesity 5B81 Approved [59]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [69]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [63]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [28]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [51]
Temozolomide DMKECZD Adenocarcinoma 2D40 Approved [68]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [52]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [70]
Amphotericin B DMTAJQE Acne vulgaris ED80 Approved [71]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [72]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Monoamine oxidase type B (MAO-B) TTGP7BY AOFB_HUMAN Inhibitor [1]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
NADPH-dependent carbonyl reductase 3 (CBR3) Main DME DEIVKZ8 CBR3_HUMAN Substrate [2]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Aflatoxin B1 aldehyde reductase member 2 (AKR7A2) OTGEDDM2 ARK72_HUMAN Biotransformations [3]
Aldo-keto reductase family 1 member B1 (AKR1B1) OTRX72TH ALDR_HUMAN Biotransformations [3]
Cytochrome P450 2A6 (CYP2A6) OT52TWG3 CP2A6_HUMAN Gene/Protein Processing [4]
Cytochrome P450 2D6 (CYP2D6) OTZJC802 CP2D6_HUMAN Gene/Protein Processing [4]
Cytochrome P450 2E1 (CYP2E1) OTHQ17JG CP2E1_HUMAN Gene/Protein Processing [4]
Dehydrogenase/reductase SDR family member 11 (DHRS11) OTU3J0ZL DHR11_HUMAN Biotransformations [5]
Dehydrogenase/reductase SDR family member 7 (DHRS7) OTV729DT DHRS7_HUMAN Biotransformations [6]

References

1 DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
2 Analysis of the substrate-binding site of human carbonyl reductases CBR1 and CBR3 by site-directed mutagenesis. Chem Biol Interact. 2009 Mar 16;178(1-3):234-41.
3 Major differences exist in the function and tissue-specific expression of human aflatoxin B1 aldehyde reductase and the principal human aldo-keto reductase AKR1 family members. Biochem J. 1999 Oct 15;343 Pt 2(Pt 2):487-504.
4 Comparison of gene expression patterns between 2,3,7,8-tetrachlorodibenzo-p-dioxin and a natural arylhydrocarbon receptor ligand, indirubin. Toxicol Sci. 2004 Jul;80(1):161-9.
5 Rabbit dehydrogenase/reductase SDR family member 11 (DHRS11): Its identity with acetohexamide reductase with broad substrate specificity and inhibitor sensitivity, different from human DHRS11. Chem Biol Interact. 2019 May 25;305:12-20. doi: 10.1016/j.cbi.2019.03.026. Epub 2019 Mar 26.
6 Biochemical properties of human dehydrogenase/reductase (SDR family) member 7. Chem Biol Interact. 2014 Jan 25;207:52-7. doi: 10.1016/j.cbi.2013.11.003. Epub 2013 Nov 16.
7 Emerging drugs for Parkinson's disease. Expert Opin Emerg Drugs. 2006 Sep;11(3):403-17.
8 Limitation of adipose tissue enlargement in rats chronically treated with semicarbazide-sensitive amine oxidase and monoamine oxidase inhibitors. Pharmacol Res. 2008 Jun;57(6):426-34.
9 Tranylcypromine: new perspectives on an "old" drug. Eur Arch Psychiatry Clin Neurosci. 2006 Aug;256(5):268-73.
10 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2490).
11 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
12 Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan. Neurotox Res. 2009 Aug;16(2):148-59.
13 Novel monoamine oxidase inhibitors, 3-(2-aminoethoxy)-1,2-benzisoxazole derivatives, and their differential reversibility. Jpn J Pharmacol. 2002 Feb;88(2):174-82.
14 Dose-dependent activation of distinct hypertrophic pathways by serotonin in cardiac cells. Am J Physiol Heart Circ Physiol. 2009 Aug;297(2):H821-8.
15 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
16 Multiple mechanisms of action: the pharmacological profile of budipine. J Neural Transm Suppl. 1999;56:83-105.
17 Different functions between human monomeric carbonyl reductase 3 and carbonyl reductase 1. Mol Cell Biochem. 2008 Aug;315(1-2):113-21.
18 Naturally occurring variants of human CBR3 alter anthracycline in vitro metabolism. J Pharmacol Exp Ther. 2010 Mar;332(3):755-63.
19 The role of carbonyl reducing enzymes in oxcarbazepine in vitro metabolism in man. Chem Biol Interact. 2014 Sep 5;220:241-7.
20 Studies on reduction of S-nitrosoglutathione by human carbonyl reductases 1 and 3. Chem Biol Interact. 2011 May 30;191(1-3):95-103.
21 Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity. Eur J Drug Metab Pharmacokinet. 2011 Mar;36(1):1-16.
22 Inhibition of CYP2E1 catalytic activity in vitro by S-adenosyl-L-methionine. Biochem Pharmacol. 2005 Apr 1;69(7):1081-93.
23 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
24 Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol Toxicol. 2012 Apr;28(2):69-87.
25 An in vitro model of human acute ethanol exposure that incorporates CXCR3- and CXCR4-dependent recruitment of immune cells. Toxicol Sci. 2013 Mar;132(1):131-41.
26 Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
27 Proteomic analysis of hepatic effects of phenobarbital in mice with humanized liver. Arch Toxicol. 2022 Oct;96(10):2739-2754. doi: 10.1007/s00204-022-03338-7. Epub 2022 Jul 26.
28 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
29 Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors. Chem Biol Interact. 2004 Apr 15;147(3):331-40.
30 Human recombinant cytochrome P450 enzymes display distinct hydrogen peroxide generating activities during substrate independent NADPH oxidase reactions. Toxicol Sci. 2014 Oct;141(2):344-52. doi: 10.1093/toxsci/kfu133. Epub 2014 Jul 24.
31 Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl). 1999 Dec;147(3):300-5. doi: 10.1007/s002130051171.
32 Effect of penicillin-based antibiotics, amoxicillin, ampicillin, and piperacillin, on drug-metabolizing activities of human hepatic cytochromes P450. J Toxicol Sci. 2016 Feb;41(1):143-6.
33 Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metab Dispos. 2011 Nov;39(11):2049-56. doi: 10.1124/dmd.111.041384. Epub 2011 Aug 5.
34 Identification of human P450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its kinetic parameters and inhibition constants. Biol Pharm Bull. 2005 Feb;28(2):328-34.
35 Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl. Eur J Clin Pharmacol. 2007 Feb;63(2):159-63.
36 Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
37 Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
38 Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clin Pharmacol Ther. 2001 Oct;70(4):327-35.
39 Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro. Drug Metab Dispos. 2003 Jun;31(6):768-72.
40 Cyp2a6 is a principal enzyme involved in hydroxylation of 1,7-dimethylxanthine, a main caffeine metabolite, in humans. Drug Metab Dispos. 2005 Sep;33(9):1361-6. doi: 10.1124/dmd.105.004796. Epub 2005 Jun 24.
41 Mimicking gene defects to treat drug dependence. Ann N Y Acad Sci. 2000;909:233-46. doi: 10.1111/j.1749-6632.2000.tb06685.x.
42 Expression of CYP2A6 in tumor cells augments cellular sensitivity to tegafur. Jpn J Cancer Res. 2001 May;92(5):524-8. doi: 10.1111/j.1349-7006.2001.tb01125.x.
43 CYP1A1/1B1 and CYP2A6/2A13 activity is conserved in cultures of differentiated primary human tracheobronchial epithelial cells. Toxicol In Vitro. 2011 Jun;25(4):922-9.
44 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
45 Measurement of 4-hydroxylation of ifosfamide in human liver microsomes using the estimation of free and protein-bound acrolein and codetermination of keto- and carboxyifosfamide. J Cancer Res Clin Oncol. 2002 Jul;128(7):385-92.
46 Integrated 'omics analysis reveals new drug-induced mitochondrial perturbations in human hepatocytes. Toxicol Lett. 2018 Jun 1;289:1-13.
47 Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes. Xenobiotica. 2009 Nov;39(11):795-802. doi: 10.3109/00498250903171395.
48 A novel single nucleotide polymorphism altering stability and activity of CYP2a6. Biochem Biophys Res Commun. 2001 Mar 2;281(3):810-4. doi: 10.1006/bbrc.2001.4422.
49 Insights into the transcriptional regulation of the anthracycline reductase AKR7A2 in human cardiomyocytes. Toxicol Lett. 2019 Jun 1;307:11-16.
50 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
51 Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
52 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
53 Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
54 Apoptosis induced by piroxicam plus cisplatin combined treatment is triggered by p21 in mesothelioma. PLoS One. 2011;6(8):e23569.
55 Increased mitochondrial ROS formation by acetaminophen in human hepatic cells is associated with gene expression changes suggesting disruption of the mitochondrial electron transport chain. Toxicol Lett. 2015 Apr 16;234(2):139-50.
56 Reproducible chemical-induced changes in gene expression profiles in human hepatoma HepaRG cells under various experimental conditions. Toxicol In Vitro. 2009 Apr;23(3):466-75. doi: 10.1016/j.tiv.2008.12.018. Epub 2008 Dec 30.
57 Inducible protection of human astrocytoma 1321N1 cells against hydrogen peroxide and aldehyde toxicity by 7-hydroxycoumarin is associated with the upregulation of aldo-keto reductases. Neurotoxicology. 2012 Oct;33(5):1368-74.
58 Human aldo-keto reductase AKR7A2 protects against the cytotoxicity and mutagenicity of reactive aldehydes and lowers intracellular reactive oxygen species in hamster V79-4 cells. Chem Biol Interact. 2012 Jan 5;195(1):25-34. doi: 10.1016/j.cbi.2011.09.007. Epub 2011 Oct 5.
59 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
60 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
61 Classification of heavy-metal toxicity by human DNA microarray analysis. Environ Sci Technol. 2007 May 15;41(10):3769-74.
62 Posttranslational glutathiolation of aldose reductase (AKR1B1): a possible mechanism of protein recovery from S-nitrosylation. Chem Biol Interact. 2009 Mar 16;178(1-3):250-8. doi: 10.1016/j.cbi.2008.11.007. Epub 2008 Nov 18.
63 Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
64 Keratinocyte gene expression profiles discriminate sensitizing and irritating compounds. Toxicol Sci. 2010 Sep;117(1):81-9.
65 Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
66 Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
67 Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
68 Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
69 Gene expression profile induced by arsenic trioxide in chronic lymphocytic leukemia cells reveals a central role for heme oxygenase-1 in apoptosis and regulation of matrix metalloproteinase-9. Oncotarget. 2016 Dec 13;7(50):83359-83377.
70 Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
71 Differential expression of microRNAs and their predicted targets in renal cells exposed to amphotericin B and its complex with copper (II) ions. Toxicol Mech Methods. 2017 Sep;27(7):537-543. doi: 10.1080/15376516.2017.1333554. Epub 2017 Jun 8.
72 Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.